Source: Multiple Myeloma News — ScienceDaily
A personalized cancer vaccine raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial.
Read More